SCHEDULE 13G
0001831942
XXXXXXXX
LIVE
Common Stock, $0.0001 par value
12/10/2024
0001213037
Cardiff Oncology, Inc.
14147L108
11055 FLINTKOTE AVENUE
SAN DIEGO
CA
92121
Rule 13d-1(c)
COMMODORE CAPITAL LP
DE
0.00
5384616.00
0.00
5384616.00
5384616.00
N
8.1
IA
See Item 2 for additional information.
Commodore Capital Master LP
E9
0.00
5384616.00
0.00
5384616.00
5384616.00
N
8.1
OO
See Item 2 for additional information.
Cardiff Oncology, Inc.
11055 FLINTKOTE AVENUE, SAN DIEGO, CALIFORNIA, 92121.
This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the "Firm") and Commodore Capital Master LP, a Cayman Islands exempted limited partnership ("Commodore Master"). The Firm is the investment manager to Commodore Master. As of December 10, 2024, the Firm may be deemed to beneficially own an aggregate of 5,384,616 shares of common stock, $0.0001 par value (the "Common Stock"), of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 66,524,182 shares of Common Stock reported as issued and outstanding in the Issuer's Rule 424(b)(5) Prospectus Supplement filed with the Securities and Exchange Commission on December 11, 2024.
The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.
The Firm is a Delaware limited partnership and Commodore Master is a Cayman Islands exempted limited partnership.
Y
5384616.00
8.1
0
5384616.00
0
5384616.00
Y
N
Y
Y
Y
Y
N
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibit 1 - JOINT FILING AGREEMENT
COMMODORE CAPITAL LP
/s/ Michael Kramarz
12/17/2024
Commodore Capital Master LP
/s/ Michael Kramarz
12/17/2024